SFSPM Novembre Valeur prédictive et pronostique de l infiltrat immunitaire dans les cancers du sein traités par chimiothérapie néoadjuvante

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "SFSPM Novembre Valeur prédictive et pronostique de l infiltrat immunitaire dans les cancers du sein traités par chimiothérapie néoadjuvante"

Transcription

1 SFSPM Novembre 217 Valeur prédictive et pronostique de l infiltrat immunitaire dans les cancers du sein traités par chimiothérapie néoadjuvante Dr Fabien REYAL Service de Chirurgie INSERM U932 Immunity and Cancer Institut Curie

2 Tumor infiltration in the neoadjuvant setting Role of tumor-infiltrating lymphocytes (TILs) High levels of TILs at diagnosis : better response to NAC Better prognosis (triple negative breast cancers (TNBC) and HER2-positive BC) TILs following neoadjuvant chemotherapy (NAC)? Myashita Dieci Loi Hamy BC subtype TNBC TNBC TNBC HER2-pos Numbers n=131 n=278 n=111 n=175 Pairs pre & post n=78 n=19 n=39 n=175 Analysis in pcr patients No No No Yes 2

3 Tumor infiltration and response to treatment in breast cancer NEOREP cohort Institut Curie n=718 Microbiopsy BEFORE Neoadjuvant chemotherapy DURING Surgery AFTER TIL baseline TILs dynamics TIL residual Identify patterns of immune infiltration related to response to treatment and prognosis

4 Patients characteristics NEOREP cohort n=718 Mean age : 48 y.o TNBC 44% Luminal 31% HER2 24% Median tumor size: 45mm Anthra taxanes (8.4%) N=718 BMI class BMI<19 41 (5.7) BMI: 19 to (57.7) BMI: 25 to (23.2) BMI>3 96 (13.4) Tumor size 45. (2.5) Tumor size T1 47 (6.5) T2 482 (67.1) T3 189 (26.3) Clinical node status N 282 (39.3) N1-N2-N3 435 (6.7) BC subtype Luminal 223 (31.1) TNBC 32 (44.6) HER2 175 (24.4) Histology Ductal carcinoma NST 661 (92.6) Other 53 (7.4) Grade Grade I-II 211 (3.1) Grade III 491 (69.9) NAC regimen Anthracyclines based regimens 61 (8.5) Anthracyclines-taxanes regimens 577 (8.4) Others 8 (11.1)

5 Microbiopsy before NAC TIL=2% Microbiopsy before NAC TIL>6% 5

6 Surgical Specimen after NAC TIL=2% Surgical Specimen after NAC TIL>6%6

7 Lymphocyte PBC before neoadjuvant chemotherapy is a rare entity Lymphocyte predominant breast cancer Cut-off stromal TILs : 5 or 6% luminal TNBC HER BC subtype luminal TNBC HER Baseline TIL levels (%) Luminal 2% TN 18% HER2-positive 1%

8 Baseline TILs vary by BC subtype Baseline TILs are associated with agressive tumor characteristics A * B C * D * E * BC subtype 5 25 Clinical tumor size 5 25 Grade 5 25 Pre NAC mitotic index 5 25 Invasive tumor cellularity 5 25 luminal TNBC HER2 T1 T2 T3 Grade I II Grade III < >22 <=6% > 6%

9 Response to treatment

10 luminal TNBC HER2 luminal TNBC HER2 Baseline TIL levels* are associated with pcr Pre NAC str TILs (%) Pre NAC str TILs (%) c Post NAC str TILs (%) Pre NAC str TILs (%) d Post NAC str TILs (%) a b a b Pre NAC str TILs (%) ** pcr No pcr 6 6 pcr No pc Luminal and TNBC and NOT in HER2+ BC Significant interaction by BC subtype (p=.4) pcr No pcr

11 luminal TNBC HER2 luminal TNBC HER2 Baseline TIL levels* are associated with RCB a b c 6 6 a b Pre NAC str TILs (%) Pre NAC str TILs (%) Pre NAC str TILs (%) Pre NAC str TILs (%) pcr RCB I RCB II RCB III 4 4 c d In luminal and TNBC, NOT in HER2+ BC 6 11 pcr RCB I RCB II RCB III ) )

12 2 2nd tert 3rd tert % p 2 2 Baseline TILs levels are associated with pcr in luminal and TNBC not in HER2-positive BC luminal TNBC HER2 <6% =>6% % p luminal TNBC HER % =>5% B 1 t rt t t % pcr Str TILs (,1] (1,2] (2,3] (3,4] (4,5] (5,6] (6,7] (7,8] (8,9] luminal TNBC HER2 12

13 TILs dynamic

14 TILs levels decrease after neoadjuvant chemotherapy A Stromal TIL levels (%) Pre All Post B Luminal Pre Post C TNBC Pre Post D HER2 Pre Post

15 TILs dynamics is strongly correlated with baseline TILs levels TILs changes before and after NAC TILs changes before and after NAC, by baseline TILs (1% classes) 1 (,1] (1,2] (2,3] (3,4] (4,5] (5,6] (6,7] (7,8] (8,9] Baseline TIL levels (by 1% increment) 15

16 irrespective of response to treatment No pcr pcr TILs variation (abs. val.) 5 5 (,1] (1,2] (2,3] (3,4] (4,5] (5,6] (6,7] (7,8] (8,9] Baseline TILs 16

17 A high decrease in stromal TIL levels is associated with pcr 5 Change in str TIL levels (abs val) 5 pcr pcr No pcr

18 High baseline TILs and high decrease of lymphocytes after NAC are associated with pcr Median Ly density Change Ly density 1 75 cancer value stromal lymphocytes 18

19 Post-NAC stromal TILs

20 Lymphocyte-predominant breast Cancer is even rarer after NAC than before 1 luminal TNBC HER % cases 5 TILs levels (9,1] (8,9] (6,7] (5,6] (4,5] (3,4] (2,3] (1,2] (,1] TNBC luminal HER Post NAC TILs (%) Luminal 1% TN 4% HER2-positive 1%

21 Post-NAC TILs are higher in tumors with residual disease than in pcr specimens perc_stromal_lymphocyte2 Post NAC TILs (%) A perc_stromal_lymphocyte2 Post NAC TILs (%) luminal TNBC HER2 B pcr No pcr Post NAC TILs (%) C luminal TNBC HER2 pcr No pcr pcr No pcr pcr No pcr Post NAC TILs (%) D

22 luminal TNBC HER2 luminal TNBC HER2 Pre 2 Pre 2 Higher post-nac TIL levels are associated with increasing RCB only in HER2-positive BC pcr RCB I RCB II RCB III a b c c d Post NAC str TILs (%) Post NAC str TILs (%) luminal TNBC Post NAC str TILs (%) Post NAC str TILs (%) pcr RCB I RCB II RCB III NS HER2 4 2 (P interaction =.4) pcr RCB I RCB II RCB III

23 Impact on prognosis 23

24 E TNBC F E TNBC Luminal F E Luminal HER2 F. < 2% => 2% TILS (cut off: 2%) + < 2% + => 2% p = Time number at risk %) TILS + TILS (cut off: 3%) + < 3% < 2% p =.17 p = => => 3% 2% Time Time number at at risk risk < 3% < 2% => => 3% 2% %) TILS + (cut off: TILS (cut off: 3%) < 3% + < 2% p =.79p =.39 + => 3% + => 2% Time Time number number at risk at risk < 3% < 2% => 3% => 2% C TNBC D C TNBC Luminal D C Luminal HER2 D Disease free survival < 4% => 4% TILS (cut off: 4%) + < 4% + => 4% p = Time number at risk Disease free survival Disease free survival TILS TILS (cut off: 5%) 4%) + + < 5% < 4% + + => => 5% 4% p = 4e Time Time number at at risk risk p =.4 < 5% < 4% => => 5% 4% Disease free survival Disease free survival TILS (cut off: TILS (cut off: 5%) 4%) + < 5% + < 4% + => 5% + => 4% p =.23p = Time Time number number at risk at risk < 5% < 4% => 5% => 4%

25 Log relative Hazard < 2% Baseline stromal TIL levels are associated with DFS in TNBC => 2% number at risk < 3% => 3% n C TNBC D Disease free survival Disease free survival.5.25 TILS (cut off: 4%) + < 4% + => 4% p =.1.. Baseline str TILs Time number at risk n < 4% => 4% < 5% => 5%

26 HER2 luminal TNBC Log relative Hazard Baseline stromal TIL levels are associated with DFS in TNBC HER2 luminal B 1 Str TILs 1st quart 2nd quart 3rd quart 4th quart % pcr Baseline str TILs luminal TNBC 26

27 Post-NAC TILs are NOT associated with DFS, but this effect differs by BC subtype - Significant interaction with BC subtype - Effect of post-nac TILs on DFS different in TNBC / HER2-positive (P interaction =.4) - Effect linear : cut-off unknown? Adverse impact of high post-nac TILs in RD in HER2-positive BC, but trend to protective effect in TNBC 27

28 Take home messages Confirmation association pre-nac TILs pcr Dynamics : The highest baseline TILs are, the highest their level decrease High TILs decrease correlates with pcr Different prognostic value pre and post-nac = > Complex interactions BC subtype and TILs TILs subsetting is pivotal to understand mechanisms of resistance to treatment Assessment pre NAC & post NAC should become routine practice 28

29 U932 Immunity and Cancer Anne-sophie Hamy-Petit Hélène Bonsang Kitzis Department of tumour biology Marick Laé Lucian Topiu Diane Decroze 29

30 Univariate Multivariate name levels OR 95%CI pval OR 95%CI p Age <45 y.o y.o.97 [ ].877 >55 y.o 1.4 [ ].11 Menopausal status postmenopausal 1 premenopausal.8 [ ].193 BMI class BMI: 19 to 25 1 BMI<19.56 [ ].156 BMI: 25 to 3.76 [ ].186 BMI>3.9 [ ].69 Tumor size (2 cl) T1-T2 1 T3.8 [ ].245 Clinical nodal status N 1 N1-N2-N3.9 [ ].546 ER status ER negative 1 ER positive.2 [ ] <.1 PR status PR negative 1 PR positive.13 [ ] <.1 HER2 status HER2 negative 1 HER2 positive 1.94 [ ] <.1 BC subtype TNBC 1 1 luminal.8 [ ] <.1.9 [ ] <.1 HER2 1.2 [ ] [ ].958 Histology ductal 1 other.82 [ ].543 Grade Grade I-II 1 Grade III 2.71 [ ] <.1 ki67 ki67<2 1 ki67>= [ ].51 NAC regimen Anthracyclines based regimens 1 Anthracyclines-taxanes regimens.98 [ ].936 Others 1.32 [ ].456 Pre-NAC mitotic index 3 Mitotic index <= 1 1 Mitotic index [ ].187 Mitotic index > [ ].1 Pre-NAC tumor cellularity (inv.) <= Pre-NAC tumor cellularity 6% 1 Pre-NAC tumor cellularity (inv.) > 6%.94 [ ].733 IS component (pre NAC) No pre-nac in situ component 1 Pre-NAC in situ component.83 [ ].417 Str TIL levels (continuous) 1.3 [ ] < [ ] <.1 Multivariate analysis pcr Whole population Baseline TILs (continuous or cutoff 4%) BC subtype 3

31 TNBC Univariate Multiivariate TNBC Class HR CI p p HR CI p Pre-NAC parameters Age, years < [ ].93 >55.84 [ ].55 Menopause status Post 1.47 Pre 1.18 [ ].47 BMI class BMI < BMI>= [ ].26 Tumor size T1-T2 1 <.1 T [ ] <.1 Clinical node status N 1.15 N1-N2-N [ ].15 Histology Ductal carcinoma NST 1.44 Other 1.34 [ ].44 Grade Grade I-II 1.6 Grade III 1.19 [ ].6 Ki 67 <2% % 1.32 [ ].52 Pre-NAC mitotic index < [ ].27 > [ ].17 Pre-NAC inv. tumor cellularity 6% 1.19 > 6%.74 [ ].19 Pre-NAC str TILs (cut-off 4%) < 4% 1 < %.35 [ ] <.1.39 [ ].2 Post-NAC parameters pcr No pcr 1 <.1 pcr.22 [ ] <.1 RCB index pcr 1 <.1 RCB-I 1.39 [ ] RCB-II 3.52 [ ] < [ ].626 RCB-III [ ] < [ ].82 Post-NAC Str TILS (cut-off 25%) str TILs 25% str TILs > 25% Post-NAC Mitotic index 1 1 < [ ] [ ].27 Multivariate analysis DFS TNBC Baseline TILs RCB Post-NAC mitotic index > [ ] < [ ] <.1 Post-NAC inv. tumor cellularity 3% 1.7 > 3% 1.61 [ ].7 Post-NAC Str TILS (continuous).99 [ ].79

32 HER2 Univariate Multiivariate TNBC Class HR CI p p HR CI p Pre-NAC parameters Age, years < [ ].62 >55.42 [ ].27 Menopause status Post 1.38 Pre 1.58 [ ].38 BMI class BMI < 25 1 < BMI>= [ ] [ ].2 Tumor size T1-T T [ ].15 Clinical node status N 1.57 N1-N2-N [ ].57 ER status Negative 1.81 Positive 1.12 [ ].81 PR status Negative 1.74 Positive.84 [ ].74 Grade Grade I-II Grade III.32 [ ].2.18 [ ].2 Pre-NAC mitotic index < [ ].54 >22.56 [ ].36 Pre-NAC inv. tumor cellularity 6% 1.7 > 6%.83 [ ].7 Pre-NAC str TILs (continuous).61 Pre-NAC str TILs (cut-off 4%) < 4% 1.8 4% 1.14 [ ].8 Post-NAC parameters pcr No pcr 1 <.1 pcr.9 [.1 -.7].2 RCB index pcr 1 <.1 RCB-I 3.29 [ ].4 RCB-II 11.1 [ ].2 RCB-III [ ] <.1 Post-NAC Str TILS (cut-off 25%) str TILs 25% 1 < Multivariate analysis DFS HER2 Post-NAC TILs Grade BMI str TILs > 25% 5.5 [ ] < [ ].1 Post-NAC Mitotic index [ ].66 > [ ].1 Post-NAC inv. tumor cellularity 3% 1.13 > 3% 2.7 [ ].13 Post-NAC Str TILS (continuous) 1 <.1 32

Impact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer

Impact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer Impact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer Rachna Raman, MD, MS Fellow physician University of Iowa hospitals and clinics

More information

UK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin

UK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University

More information

TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017

TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other

More information

Residual cancer burden in locally advanced breast cancer: a superior tool

Residual cancer burden in locally advanced breast cancer: a superior tool ABSTRACT Objectives Locally advanced breast cancer (LABC) poses a difficult clinical challenge with an overall poor long-term prognosis. The strength of the association between tumour characteristics,

More information

Gábor CSERNI. 1. Bács-Kiskun County Teaching Hospital, Kecskemét 2. University of Szeged, Szeged

Gábor CSERNI. 1. Bács-Kiskun County Teaching Hospital, Kecskemét 2. University of Szeged, Szeged Lymphocytes infiltrant la tumeur (TIL) sur micro-biopsies et pièces opératoires Quel impact clinique? Quels moyens de mise en évidence? Comment restituer les résultats? TILs - Clinical impact / Evaluation

More information

PMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center

PMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic

More information

10/15/2012. Biologic Subtypes of TNBC. Topics. Topics. Histopathology Molecular pathology Clinical relevance

10/15/2012. Biologic Subtypes of TNBC. Topics. Topics. Histopathology Molecular pathology Clinical relevance Biologic Subtypes of TNBC Andrea L. Richardson M.D. Ph.D. Brigham and Women s Hospital Dana-Farber Cancer Institute Harvard Medical School Boston, MA Topics Histopathology Molecular pathology Clinical

More information

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers 日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu

More information

SCIENCE CHINA Life Sciences

SCIENCE CHINA Life Sciences SCIENCE CHINA Life Sciences RESEARCH PAPER April 2013 Vol.56 No.4: 335 340 doi: 10.1007/s11427-013-4435-y Risk factors of recurrence in small-sized, node negative breast cancer in young women: a retrospective

More information

Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy

Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy Sung-Bae Kim, MD, PhD Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea DISCLOSURE

More information

Circulating Tumor Cells in non- Metastatic Triple Negative Breast Cancer

Circulating Tumor Cells in non- Metastatic Triple Negative Breast Cancer Circulating Tumor Cells in non- Metastatic Triple Negative Breast Cancer Carolyn Hall, Ph.D. Department of Surgical Oncology The University of Texas MD Anderson Cancer Center Triple Negative Breast Cancer

More information

Evaluación de la respuesta patológica completa tras tratamiento neoadyuvante en cáncer de mama. José Palacios Calvo Servicio de Anatomía Patológica

Evaluación de la respuesta patológica completa tras tratamiento neoadyuvante en cáncer de mama. José Palacios Calvo Servicio de Anatomía Patológica Evaluación de la respuesta patológica completa tras tratamiento neoadyuvante en cáncer de mama José Palacios Calvo Servicio de Anatomía Patológica E-Cadherin HER2 HER2 p63 Pathological Response Pathological

More information

Present Role of Immunohistochemistry in the. Subtypes. Beppe Viale European Institute of Oncology University of Milan Milan-Italy

Present Role of Immunohistochemistry in the. Subtypes. Beppe Viale European Institute of Oncology University of Milan Milan-Italy Present Role of Immunohistochemistry in the Classification of Molecular Subtypes Beppe Viale European Institute of Oncology University of Milan Milan-Italy We know it is many diseases Breast cancer is

More information

Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience

Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell

More information

Enterprise Interest Speaker and consultant for Astrazeneca, MSD, BMS, Roche, Pfizer, Novartis, Sanofi Resarch grants from BMS, Roche, MSD, Novartis

Enterprise Interest Speaker and consultant for Astrazeneca, MSD, BMS, Roche, Pfizer, Novartis, Sanofi Resarch grants from BMS, Roche, MSD, Novartis Enterprise Interest Speaker and consultant for Astrazeneca, MSD, BMS, Roche, Pfizer, Novartis, Sanofi Resarch grants from BMS, Roche, MSD, Novartis Centre Jean Perrin Centre de Lutte contre le Cancer d'auvergne

More information

Kathy Albain, MD. Chemotherapy in Luminal Breast Cancer: Who Benefits? Loyola University Chicago Stritch School of Medicine

Kathy Albain, MD. Chemotherapy in Luminal Breast Cancer: Who Benefits? Loyola University Chicago Stritch School of Medicine Chemotherapy in Luminal Breast Cancer: Who Benefits? Kathy Albain, MD Loyola University Chicago Stritch School of Medicine, Director, Breast Clinical Research Program, Cardinal Bernardin Cancer Center,

More information

2014 San Antonio Breast Cancer Symposium Review

2014 San Antonio Breast Cancer Symposium Review 2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01

More information

Prognostic and Predictive Factors

Prognostic and Predictive Factors Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Prognostic and Predictive Factors Prognostic and Predictive Factors Version 2002: Thomssen / Harbeck Version 2003 2009: Costa

More information

ADAPT. Adjuvant Dynamic marker- Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer

ADAPT. Adjuvant Dynamic marker- Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer ADAPT Adjuvant Dynamic marker- Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer Therapieindikation gesteuert durch prognostische Information

More information

Morphological and Molecular Typing of breast Cancer

Morphological and Molecular Typing of breast Cancer Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological

More information

Triple negative breast cancer Biology and targeted therapy

Triple negative breast cancer Biology and targeted therapy Triple negative breast cancer Biology and targeted therapy MR SCI MED DR I BOŽOVIĆ -SPASOJEVIĆ INSTITUT ZA ONKOLOGIJU I RADIOLOGIJU SRBIJE I VA N A B O Z O V I C @ O U T L O O K. C O M Current challanges

More information

Adjuvant chemotherapy in older breast cancer patients: how to decide?

Adjuvant chemotherapy in older breast cancer patients: how to decide? Adjuvant chemotherapy in older breast cancer patients: how to decide? H. Wildiers University Hospitals Leuven Belgium Wildiers H, Kunkler I, Lancet Oncol 2007 Biganzoli L, Wildiers H, Lancet Oncol. 2012

More information

Extended Hormonal Therapy

Extended Hormonal Therapy Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early

More information

Molecular in vitro diagnostic test for the quantitative detection of the mrna expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue.

Molecular in vitro diagnostic test for the quantitative detection of the mrna expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue. Innovation for your breast cancer diagnostics PGR G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C ERBB2

More information

Triple Negative Breast cancer New treatment options arenowhere?

Triple Negative Breast cancer New treatment options arenowhere? Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no

More information

Breast Cancer Statistics

Breast Cancer Statistics 1 in 8 Breast Cancer Statistics Incidence Mortality Prevalence 2 Breast Cancer Incidence Breast Cancer Mortality Breast Cancer Prevalence ~$100,000 Female Breast Anatomy Breasts consist mainly of fatty

More information

Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer

Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Kathy S. Albain, MD, FACP Professor of Medicine Dean s Scholar Loyola University Chicago Stritch School of Medicine Cardinal Bernardin

More information

Mammographic density and risk of breast cancer by tumor characteristics: a casecontrol

Mammographic density and risk of breast cancer by tumor characteristics: a casecontrol Krishnan et al. BMC Cancer (2017) 17:859 DOI 10.1186/s12885-017-3871-7 RESEARCH ARTICLE Mammographic density and risk of breast cancer by tumor characteristics: a casecontrol study Open Access Kavitha

More information

Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot

Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999

More information

A new way of looking at breast cancer tumour biology

A new way of looking at breast cancer tumour biology A new way of looking at breast cancer tumour biology Contents Intrinsic subtypes of breast cancer 3 Gene expression assays 3 Basis of the Prosigna test 4 Information provided by Prosigna 5 The accuracy

More information

4/13/2010. Silverman, Buchanan Breast, 2003

4/13/2010. Silverman, Buchanan Breast, 2003 Tailoring Breast Cancer Treatment: Has Personalized Medicine Arrived? Judith Luce, M.D. San Francisco General Hospital Avon Comprehensive Breast Care Center Outline First, treatment of DCIS Sorting risk

More information

Oncotype DX MM /01/2008. HMO; PPO; QUEST 03/01/2014 Section: Other/Miscellaneous Place(s) of Service: Office

Oncotype DX MM /01/2008. HMO; PPO; QUEST 03/01/2014 Section: Other/Miscellaneous Place(s) of Service: Office Oncotype DX Policy Number: Original Effective Date: MM.12.009 12/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2014 Section: Other/Miscellaneous Place(s) of Service: Office

More information

Modified primary tumour/vessel tumour/nodal tumour classification for patients with invasive ductal carcinoma of the breast

Modified primary tumour/vessel tumour/nodal tumour classification for patients with invasive ductal carcinoma of the breast British Journal of Cancer (2011) 105, 698 708 All rights reserved 0007 0920/11 www.bjcancer.com Modified primary tumour/vessel tumour/nodal tumour classification for patients with invasive ductal carcinoma

More information

Triple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008

Triple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade

More information

Locoregional Outcomes in Clinical Stage IIB Breast Cancer After Neoadjuvant Therapy and Mastectomy With or Without Radiation

Locoregional Outcomes in Clinical Stage IIB Breast Cancer After Neoadjuvant Therapy and Mastectomy With or Without Radiation Locoregional Outcomes in Clinical Stage IIB Breast Cancer After Neoadjuvant Therapy and Mastectomy With or Without Radiation Dayssy A. Diaz, MD, Judith Hurley, MD, Isildinha Reis, PhD, Cristiane Takita,

More information

Prediction of Postoperative Tumor Size in Breast Cancer Patients by Clinical Assessment, Mammography and Ultrasonography

Prediction of Postoperative Tumor Size in Breast Cancer Patients by Clinical Assessment, Mammography and Ultrasonography Prediction of Postoperative Tumor Size in Breast Cancer Patients by Clinical Assessment, Mammography and Ultrasonography Eyad Fawzi AlSaeed 1 and Mutahir A. Tunio 2* 1 Consultant Radiation Oncology, Chairman

More information

2017 Topics. Biology of Breast Cancer. Omission of RT in older women with low-risk features

2017 Topics. Biology of Breast Cancer. Omission of RT in older women with low-risk features 2017 Topics Biology of Breast Cancer Early-stage HER2+ breast cancer-can we avoid RT? Prediction tools for locoregional recurrence Omission of RT in older women with low-risk features Local-Regional Recurrence

More information

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical

More information

Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)

Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and

More information

Immunotherapy for Breast Cancer Clinical Development

Immunotherapy for Breast Cancer Clinical Development Immunotherapy for Breast Cancer Clinical Development Laurence Buisseret, MD, PhD Breast Cancer Translational Research Laboratory Institut Jules Bordet Université Libre de Bruxelles (ULB) ESMO preceptorship

More information

Triple negative breast cancer in South Africa

Triple negative breast cancer in South Africa Triple negative breast cancer in South Africa Dr Leanne Prodehl MBChB FCS (SA) Cert GIT Student number: 337536 Department of Surgery University of the Witwatersrand Cell number: 082 320 1430 Supervisors:

More information

Appendix ZOOM Etude pour site internet

Appendix ZOOM Etude pour site internet Appendix ZOOM Etude pour site internet Indication Traitement adjuvant pour des patients présentant une mutation germinale des gènes BRCA1/2 et un risque élevé de cancer du sein primaire HER2 négatif Title

More information

Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery

Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery Breast Cancer Res Treat (2016) 160:387 391 DOI 10.1007/s10549-016-4017-3 EDITORIAL Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery Monika Brzezinska 1 Linda J.

More information

Targeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine

Targeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine 2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical

More information

Question 1 A. ER-, PR-, HER+ B. ER+, PR+, HER2- C. ER-, PR+, HER2- D. ER-, PR-, HER2- E. ER-, PR+, HER2+

Question 1 A. ER-, PR-, HER+ B. ER+, PR+, HER2- C. ER-, PR+, HER2- D. ER-, PR-, HER2- E. ER-, PR+, HER2+ Triple Negative Breast Cancer Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA Question 1 The tumor depicted on the next slide

More information

New chemotherapy drugs in metastatic breast cancer. Guy Jerusalem, MD, PhD

New chemotherapy drugs in metastatic breast cancer. Guy Jerusalem, MD, PhD New chemotherapy drugs in metastatic breast cancer Guy Jerusalem, MD, PhD MBC Patients survival over time Median survival increases over time, but is still measured in months This is not yet a chronic

More information

RADIOTHERAPY FOR STAGE II AND STAGE III BREAST CANCER PATIENTS WITH NEGATIVE LYMPH NODES AFTER PREOPERATIVE CHEMOTHERAPY AND MASTECTOMY

RADIOTHERAPY FOR STAGE II AND STAGE III BREAST CANCER PATIENTS WITH NEGATIVE LYMPH NODES AFTER PREOPERATIVE CHEMOTHERAPY AND MASTECTOMY doi:10.1016/j.ijrobp.2010.12.054 Int. J. Radiation Oncology Biol. Phys., Vol. 82, No. 1, pp. e1 e7, 2012 Copyright Ó 2012 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ - see front matter

More information

Chapter 2 The Link Between Obesity and Breast Cancer Risk: Epidemiological Evidence

Chapter 2 The Link Between Obesity and Breast Cancer Risk: Epidemiological Evidence Chapter 2 The Link Between Obesity and Breast Cancer Risk: Epidemiological Evidence 2.1 BMI and Breast Cancer Risk BMI is routinely used to qualify an individual s adiposity, yet it is simply a measure

More information

Breast cancer classification: beyond the intrinsic molecular subtypes

Breast cancer classification: beyond the intrinsic molecular subtypes Breast cancer classification: beyond the intrinsic molecular subtypes Britta Weigelt, PhD Signal Transduction Laboratory CRUK London Research Institute Summary Breast cancer heterogeneity Molecular classification

More information

Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome

Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome Emilia Montagna, 1 Patrick Maisonneuve, 2 Nicole Rotmensz, 2 Giuseppe Cancello, 1 Monica Iorfida, 1 Alessandra

More information

Clinical pathological and epidemiological study of triple negative breast cancer

Clinical pathological and epidemiological study of triple negative breast cancer International Journal of Research in Medical Sciences Ajay A et al. Int J Res Med Sci. 217 Jun;5(6):2657-2661 www.msjonline.org pissn 232-71 eissn 232-12 Original Research Article DOI: http://dx.doi.org/1.1823/232-12.ijrms2172465

More information

Clinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer

Clinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer Original Articles Jpn J Clin Oncol 2012;42(6)471 476 doi:10.1093/jjco/hys046 Advance Access Publication 3 April 2012 Clinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer Junnan Li,

More information

Summary BREAST CANCER - Early Stage Breast Cancer... 3

Summary BREAST CANCER - Early Stage Breast Cancer... 3 ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 BREAST CANCER - Early Stage Breast Cancer... 3 Large data analysis reveals similar survival outcomes with sequential

More information

FISH mcgh Karyotyping ISH RT-PCR. Expression arrays RNA. Tissue microarrays Protein arrays MS. Protein IHC

FISH mcgh Karyotyping ISH RT-PCR. Expression arrays RNA. Tissue microarrays Protein arrays MS. Protein IHC Classification of Breast Cancer in the Molecular Era Susan J. Done University Health Network, Toronto Why classify? Prognosis Prediction of response to therapy Pathogenesis Invasive breast cancer can have

More information

A case of a BRCA2-mutated ER+/HER2 breast cancer during pregnancy

A case of a BRCA2-mutated ER+/HER2 breast cancer during pregnancy ESMO Preceptorship Programme Breast Cancer Lisbon 16,17 September 2016 Emanuela Risi Sandro Pitigliani Medical Oncology Department Hospital of Prato, Istituto Toscano Tumori, Prato, Italy A case of a BRCA2-mutated

More information

Systemic Therapy Considerations in Inflammatory Breast Cancer

Systemic Therapy Considerations in Inflammatory Breast Cancer Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,

More information

Hofmann et al. Hofmann et al. Trials 2013, 14:261

Hofmann et al. Hofmann et al. Trials 2013, 14:261 WSG ADAPT adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center,

More information

Session thématisée Les Innovations diagnostiques en cancérologie

Session thématisée Les Innovations diagnostiques en cancérologie 10 èmes Journées Scientifiques du Cancéropôle Nord-Ouest 10-12 mai 2017, Deauville Session thématisée Les Innovations diagnostiques en cancérologie Les signatures multigéniques pronostiques dans le cancer

More information

Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities Sao Jiralerspong and Pamela J. Goodwin

Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities Sao Jiralerspong and Pamela J. Goodwin VOLUME 34 NUMBER 35 DECEMBER 10, 2016 JOURNAL OF CLINICAL ONCOLOGY R E V I E W A R T I C L E Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities Sao Jiralerspong and Pamela J.

More information

Breast Cancer Assays of Genetic Expression in Tumor Tissue

Breast Cancer Assays of Genetic Expression in Tumor Tissue Breast Cancer Assays of Genetic Expression in Tumor Tissue Policy Number: Original Effective Date: MM.12.009 12/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/16/2016

More information

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer ARTICLE Ki67 Index, HER2 Status, and Prognosis of Patients With Breast Cancer Maggie C. U. Cheang, Stephen K. Chia, David Voduc, Dongxia Gao, Samuel Leung, Jacqueline Snider, Mark Watson, Sherri Davies,

More information

Rationale For & Design of TAILORx. Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York

Rationale For & Design of TAILORx. Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York Rationale For & Design of TAILORx Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York Declining Breast Cancer Mortality & Event Rates in Adjuvant

More information

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer [ID767]

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer [ID767] Slides for public and projector Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer [ID767] 2nd Appraisal Committee meeting 21 June 2016 1 Issues for committee (1) Is the clinical evidence

More information

J Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION VOLUME 24 NUMBER 36 DECEMBER 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

More information

Triple Negative Breast Cancer: Part 2 A Medical Update

Triple Negative Breast Cancer: Part 2 A Medical Update Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is

More information

PET/CT in breast cancer staging

PET/CT in breast cancer staging PET/CT in breast cancer staging Anni Morsing Consultant, PhD, DMSc Rigshospitalet 1 18F- FDG PET/CT for breastcancer staging Where is the clinical impact? To which women should 18F- FDG PET/CT be offered?

More information

When do you need PET/CT or MRI in early breast cancer?

When do you need PET/CT or MRI in early breast cancer? When do you need PET/CT or MRI in early breast cancer? Elizabeth A. Morris MD FACR Chief, Breast Imaging Service Memorial Sloan-Kettering Cancer Center NY, NY Objectives What is the role of MRI in initial

More information

Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients

Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients JBUON 2015; 20(1): 28-34 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Progesterone receptor status in determining the prognosis of estrogen

More information

Introduction. Approximately 20% of invasive breast cancers

Introduction. Approximately 20% of invasive breast cancers Introduction Approximately 2% of invasive breast cancers overexpress HER2 The current standard of care for neoadjuvant therapy is dual-targeted therapy with trastuzumab and pertuzumab plus chemotherapy

More information

UNCORRECTED PROOF. Author Proof. Murali Janakiram and Hina Khan are contributed equally to this work.

UNCORRECTED PROOF. Author Proof. Murali Janakiram and Hina Khan are contributed equally to this work. Chapter No.: 12 Date: 28-8-2016 Time: 10:10 am Page: 1/20 1 12 23 Tumor Infiltrating Lymphocytes 4 as a Prognostic Predictive 5 Biomarker in Breast Cancer 6 Murali Janakiram, Hina Khan, Susan Fineberg,

More information

Mdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often

More information

DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID

DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;

More information

METRIC Study Key Eligibility Criteria

METRIC Study Key Eligibility Criteria The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).

More information

Haruo Ohtani, 1,2 Kazuko Mori-Shiraishi, 3 Morio Nakajima 3 and Hamaichi Ueki 3

Haruo Ohtani, 1,2 Kazuko Mori-Shiraishi, 3 Morio Nakajima 3 and Hamaichi Ueki 3 bs_bs_banner Pathology International 2015; 65: 644 651 doi:10.1111/pin.12355 Original Article Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance

More information

Jonathan Dickinson, LCL Xeloda

Jonathan Dickinson, LCL Xeloda Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy

More information

Positive Bone Marrow Biopsy is Associated with a Decreased Disease-Free Survival in Patients with Operable Breast Cancer

Positive Bone Marrow Biopsy is Associated with a Decreased Disease-Free Survival in Patients with Operable Breast Cancer Positive Bone Marrow Biopsy is Associated with a Decreased Disease-Free Survival in Patients with Operable Breast Cancer L Fortunato (*), A Mascaro (*), A Baldi ( ), M Farina (*), MAmini(**) ), C Vitelli

More information

J Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION VOLUME 26 NUMBER 8 MARCH 1 28 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer Cornelia Liedtke,

More information

Seigo Nakamura,M.D.,Ph.D.

Seigo Nakamura,M.D.,Ph.D. Seigo Nakamura,M.D.,Ph.D. Professor of Surgery Director of Breast Center Showa University Hospital Chairman of the board of directors Japan Breast Cancer Society Inhibition of Estrogen-Dependent Growth

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Assays of Genetic Expression in Tumor Tissue as a Technique Page 1 of 54 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Assays of Genetic Expression in Tumor Tissue

More information

Medical Policy. Description. Related Policies. Policy. Effective Date January 1, 2015 Original Policy Date December 1, 2005

Medical Policy. Description. Related Policies. Policy. Effective Date January 1, 2015 Original Policy Date December 1, 2005 2.04.36 Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date January

More information

Targeting Surgery for Known Axillary Disease. Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center

Targeting Surgery for Known Axillary Disease. Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center Targeting Surgery for Known Axillary Disease Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center Nodal Ultrasound at Diagnosis Whole breast and draining lymphatic

More information

BREAST CANCER IN YOUNG AGE IS AN ASSAMESE WOMEN INDEPENDENT PROGNOSTIC INDICATOR IN

BREAST CANCER IN YOUNG AGE IS AN ASSAMESE WOMEN INDEPENDENT PROGNOSTIC INDICATOR IN BREAST CANCER IN YOUNG AGE IS AN INDEPENDENT PROGNOSTIC INDICATOR IN ASSAMESE WOMEN Gayatri Gogoi MD Assistant Professor Deptt of Pathology Assam Medical College, Dibrugarh, Assam, India - gayatrigogoi303@gmail.com.

More information

BREAST CANCER SLIDE DECK 2017 Selected abstracts from:

BREAST CANCER SLIDE DECK 2017 Selected abstracts from: BREAST CANCER SLIDE DECK 2017 Selected abstracts from: ESMO 2017 CONGRESS ESMO 2017 CONGRESS 8 12 September 2017 8 12 September Madrid, Spain 2017 Madrid, Spain Supported by Eli Lilly and Company. Eli

More information

Survival of Triple Negative versus Triple Positive Breast Cancers: Comparison and Contrast

Survival of Triple Negative versus Triple Positive Breast Cancers: Comparison and Contrast 10.14456/apjcp.2016.191/APJCP.2016.17.8.3911 Survival of Triple Negative and Triple Positive Breast Cancers RESEARCH ARTICLE Survival of Triple Negative versus Triple Positive Breast Cancers: Comparison

More information

Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes

Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes G. Cancello, P. Maisonneuve, N. Rotmensz, G. Viale, M. G. Mastropasqua, G.

More information

Multiparameter characterization of breast carcinoma: subgross, microscopy, proteins, and genes

Multiparameter characterization of breast carcinoma: subgross, microscopy, proteins, and genes World Congress on Breast Cancer August 1-3, 2015, Birmingham, UK Multiparameter characterization of breast carcinoma: subgross, microscopy, proteins, and genes Tibor Tot Falun, Sweden Lake Varpan, Falun,

More information

Understanding and Optimizing Treatment of Triple Negative Breast Cancer

Understanding and Optimizing Treatment of Triple Negative Breast Cancer Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology Program Leader, Gastrointestinal Oncology Department

More information

Debate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest

Debate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,

More information

Authors: Thais Abreu de ALMEIDA 1, Institution:

Authors: Thais Abreu de ALMEIDA 1, Institution: Correlation of CYP2D6 s genotype and phenotype with clinicopathological characterization and impact on survival in Brazilian breast cancer population: a prospective study. Authors: Thais Abreu de ALMEIDA

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Assays of Genetic Expression in Tumor Tissue as a Technique Page 1 of 47 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Assays of Genetic Expression in Tumor Tissue

More information

Elisa V. Bandera, MD, PhD

Elisa V. Bandera, MD, PhD Elisa V. Bandera, MD, PhD Associate Professor of Epidemiology Rutgers Cancer Institute of New Jersey Rutgers School of Public Health American Institute for Cancer Research Annual Conference on Food, Nutrition,

More information

Analysing research on cancer prevention and survival. Diet, nutrition, physical activity and breast cancer survivors. In partnership with

Analysing research on cancer prevention and survival. Diet, nutrition, physical activity and breast cancer survivors. In partnership with Analysing research on cancer prevention and survival Diet, nutrition, physical activity and breast cancer survivors 2014 In partnership with Contents About World Cancer Research Fund International 1 Our

More information

ULTIMATE GBG 95 UC-0140/1606 BIG UnLock The IMmune cells ATtraction in ER+ breast cancer

ULTIMATE GBG 95 UC-0140/1606 BIG UnLock The IMmune cells ATtraction in ER+ breast cancer ULTIMATE GBG 95 UC-0140/1606 BIG 16-01 UnLock The IMmune cells ATtraction in ER+ breast cancer A PHASE II TRIAL TESTING DURVALUMAB COMBINED WITH ENDOCRINE THERAPY IN PATIENTS WITH ER+/HER2- BREAST CANCER

More information

Hormone receptor and Her2 neu (Her2) analysis

Hormone receptor and Her2 neu (Her2) analysis ORIGINAL ARTICLE Impact of Triple Negative Phenotype on Breast Cancer Prognosis Henry G. Kaplan, MD* and Judith A. Malmgren, PhD à *Swedish Cancer Institute at Swedish Medical Center; HealthStat Consulting

More information

Molecular subtypes in patients with inflammatory breast cancer; A single center experience

Molecular subtypes in patients with inflammatory breast cancer; A single center experience JBUON 05; 0(): 35-3 ISSN: 0-065, online ISSN: 4-63 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Molecular subtypes in patients with inflammatory breast cancer; A single center experience

More information

METASTASES OF PATIENTS WITH EARLY STAGES OF BREAST CANCER

METASTASES OF PATIENTS WITH EARLY STAGES OF BREAST CANCER Trakia Journal of Sciences, No 4, pp 7-76, 205 Copyright 205 Trakia University Available online at: http://www.uni-sz.bg ISSN 33-7050 (print) doi:0.5547/tjs.205.04.02 ISSN 33-355 (online) Original Contribution

More information

Will preoperative trials change future clinical practice?

Will preoperative trials change future clinical practice? Therapeutic Perspective Will preoperative trials change future clinical practice? Clin. Invest. (2011) 1(1), 59 73 Preoperative systemic (PST) has emerged from an infrequently used approach in the management

More information

Disclosure Information. Mary L. Disis

Disclosure Information. Mary L. Disis Disclosure Information Mary L. Disis I have the following financial relationships to disclose: Consultant for: VentiRx, Celgene, Emergent, EMD Serono Speaker s Bureau for: N/A Grant/Research support from:

More information